{"analyses":[{"ciLowerLimit":"0.347","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.093","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0934","paramType":"Hazard Ratio (HR)","paramValue":"0.616","statisticalComment":"Stratified","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.87","upperLimit":"12.35","value":"8.31"},{"groupId":"OG001","lowerLimit":"3.65","upperLimit":"6.83","value":"4.80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"description":"The duration of overall response was defined for each participant with a best response of CR or PR and measured from the time measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that disease is recurrent or objective disease progression or death due to any cause is observed (taking as reference for PD the smallest measurements recorded on study).","dispersionType":"95% Confidence Interval","groups":[{"description":"75 milligrams per meter squared (mg/m\\^2) doxorubicin administered intravenously (IV) on day 1 of each 21 day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21 day cycle until documented progressive disease (PD) or discontinuation for any other reason.","id":"OG000","title":"Doxorubicin + Olaratumab"},{"description":"75 mg/m\\^2 doxorubicin administered IV on day 1 of each 21 day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21 day cycle until PD or discontinuation for any other reason.","id":"OG001","title":"Doxorubicin + Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who have evaluable DoR data.","reportingStatus":"POSTED","timeFrame":"Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 33.4 Months)","title":"Duration of Overall Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}